Figure 4. MAGP2 Is Expressed in Ovarian Cancer Cells and Enhances Adhesion and Survival In Vitro.
(A) Western blot analysis of MAGP2 protein isolated from 2 normal HOSE cultures and 12 ovarian cancer cell lines.
(B) Flow cytometry analysis of αVβ3 cell surface receptor levels in select high and low MAGP2-expressing cell lines using monoclonal antibodies against αVβ3 or IgG1 isotype control.
(C) Silver staining for total protein obtained from yeast clone 10 supernatant identifies recMAGP2 as the principal secreted product following purification.
(D) Increased adhesion of A224 ovarian cells in the presence of purified recMAGP2 (p < 0.02), with reduced adhesion following anti-αVβ3 integrin antibody treatment (p < 0.01).
(E) αVβ3 integrin receptor-negative UCI107 cells displayed no significant increase in adhesion in the presence of recMAGP2.
(F) OVCA429 cell viability was evaluated with increasing concentrations of recMAGP2. Increased cell survival was seen at higher concentrations of recMAGP2 reaching a maximum at 200 ng/ml (p = 0.004). For (E) and (F), data are the mean ± SD of three independent experiments.
(G) Survival signaling in OVCA429 cells in response to treatment with recMAGP2. Differentially regulated genes were identified (red, upregulated; blue, downregulated; gray, no change).